Japan-based Otsuka Pharmaceutical has agreed to acquire Visterra, a clinical-stage biotechnology company engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, it was reported yesterday.
The deal is valued at around USD430m. It is likely to be completed in the third quarter of this year, subject to customary closing conditions.
Once the deal completes, the company will become a wholly owned subsidiary of Otsuka America, which is a US holding company and wholly owned subsidiary of Otsuka Pharmaceutical.
Otsuka is engaged in research areas, including psychiatric and neurological diseases, haematological cancers, and kidney, cardiovascular, and infectious diseases.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy